糖心vlog

[Skip to Navigation]
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
糖心vlog Home
JAMA Oncology
Sign In
New Online Current Issue Past Issues
糖心vlog Statement on Potentially Offensive Content

October 2024 - April 2015

Decade

Year

Issue

February 2022, Vol 8, No. 2, Pages 192-308

Original Investigation

Immune-Mediated Diseases Associated With Cancer Risks

Ming-ming He, MD; Chun-Han Lo, MD, MPH; Kai Wang, MD, PhD; et al.
Abstract Full Text
open access
JAMA Oncol. 2022;8(2):209-219. doi:10.1001/jamaoncol.2021.5680

This cohort study uses data from the UK Biobank to assess the associations of immune-mediated diseases with risk of total and individual cancers and of organ-specific immune-mediated diseases with risk of local and extralocal cancers.

Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades

Sophia C. Kamran, MD; Andrzej Niemierko, PhD; Curtiland Deville Jr, MD; et al.
Abstract Full Text
free access
JAMA Oncol. 2022;8(2):221-229. doi:10.1001/jamaoncol.2021.6011

This cross-sectional study uses data from the Association of American Medical Colleges to report trends in academic faculty representation by sex and by race and ethnicity for radiation oncology and medical oncology departments.

Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration Database

Mitchell S. Anscher, MD; Shaily Arora, PharmD; Chana Weinstock, MD; et al.
Abstract Full Text
free access
JAMA Oncol. 2022;8(2):232-240. doi:10.1001/jamaoncol.2021.6439

This pooled analysis assesses whether an increased risk of serious adverse events is associated with radiation therapy given within 90 days prior to an immune checkpoint inhibitor.

Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine鈥揜efractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial

Yansong Lin, MD, PhD; Shukui Qin, MD, PhD; Zhiyong Li, MM; et al.
Abstract Full Text
open access
JAMA Oncol. 2022;8(2):242-250. doi:10.1001/jamaoncol.2021.6268

This randomized clinical trial evaluated the use of apatinib vs placebo in patients with locally advanced or metastatic radioactive iodine鈥搑efractory differentiated thyroid cancer.

Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial

Xiangyun Zong, MD, PhD; Yang Yu, MD; Hongjian Yang, MD; et al.
Abstract Full Text
free access
JAMA Oncol. 2022;8(2):252-258. doi:10.1001/jamaoncol.2021.6214

This randomized clinical trial examines the effect of administering gonadotropin-releasing hormone analogs during treatment with chemotherapy in premenopausal Chinese women with breast cancer on reducing ovarian impairment.

Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial

Alyx B. Porter, MD; Heshan Liu, MS; Sadhna Kohli, PhD; et al.
Abstract Full Text
free access
JAMA Oncol. 2022;8(2):259-267. doi:10.1001/jamaoncol.2021.5948

This randomized clinical trial examines the efficacy of armodafinil in reducing fatigue in patients with high-grade glioma and moderate-to-severe fatigue.

Association of Antiparietal Cell and Anti-Intrinsic Factor Antibodies With Risk of Gastric Cancer

Minkyo Song, MD, PhD; M. Constanza Camargo, PhD; Hormuzd A. Katki, PhD; et al.
Abstract Full Text
open access
JAMA Oncol. 2022;8(2):268-274. doi:10.1001/jamaoncol.2021.5395

This cohort study seeks to determine the association of prediagnostic autoantibodies to gastric mucosa with gastric cancer risk.

Brief Report

Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Robert J. Motzer, MD; Thomas Powles, MD; Michael B. Atkins, MD; et al.
Abstract Full Text
free access has audio
JAMA Oncol. 2022;8(2):275-280. doi:10.1001/jamaoncol.2021.5981

This phase 3 randomized clinical trial reports the final overall survival, safety, and exploratory analyses of the association of transcriptomic subsets with overall survival from IMmotion151.

  • Podcast: Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study

Julie Tsu-Yu Wu, MD, PhD; Jennifer La, PhD; Westyn Branch-Elliman, MD, MMSc; et al.
Abstract Full Text
open access has active quiz
JAMA Oncol. 2022;8(2):281-286. doi:10.1001/jamaoncol.2021.5771

This cohort study assesses the association between SARS-CoV-2 vaccination and SARS-CoV-2 infections among a population of Veterans Affairs (VA) patients with cancer.

Research Letter

Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

Yakir Rottenberg, MD, MPH; Albert Grinshpun, MD, MSc; Iddo Z. Ben-Dov, MD, PhD; et al.
Abstract Full Text
free access has active quiz
JAMA Oncol. 2022;8(2):300-301. doi:10.1001/jamaoncol.2021.6764

This cohort study evaluates the short-term humoral response to a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing acute systemic therapy for solid tumors.

Special Communication

Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies

Samantha Brown, MS; Jessica A. Lavery, MS; Ronglai Shen, PhD; et al.
Abstract Full Text
JAMA Oncol. 2022;8(2):287-291. doi:10.1001/jamaoncol.2021.5153

This Special Communication illustrates the consequences of not adjusting for left truncation and describes an approach to correct for length bias.

Review

Treatment Selection in First-line Metastatic Renal Cell Carcinoma鈥擳he Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review

Vishal Navani, MA, MBBS, MRCP; Daniel Y. C. Heng, MD, MPH
Abstract Full Text
JAMA Oncol. 2022;8(2):292-299. doi:10.1001/jamaoncol.2021.4337

This narrative review discusses recent advances in use of combination therapy for patients with metastatic clear cell renal cell carcinoma.

Viewpoint

Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination

Evangelos Terpos, MD, PhD; S. Vincent Rajkumar, MD; Nelson Leung, MD
Abstract Full Text
free access
JAMA Oncol. 2022;8(2):201-202. doi:10.1001/jamaoncol.2021.5942

This Viewpoint discusses the benefits of titer testing for anti鈥揝ARS-CoV-2 antibodies in patients with severe immunosuppression, including patients with multiple myeloma, following COVID-19 vaccination.

Reconceptualizing Risk-Benefit Assessment of Novel Cancer Therapies to Expand Global Access and Reduce Worldwide Mortality

Rebecca J. DeBoer, MD, MA; Hope S. Rugo, MD; Lawrence N. Shulman, MD
Abstract Full Text
JAMA Oncol. 2022;8(2):203-204. doi:10.1001/jamaoncol.2021.5945

This article discusses the availability of novel cancer therapies and health care infrastructure in high-income vs low- and middle-income countries.

The Urgent Need for Affordability Curricula at US Medical Schools: The Cost of Avoiding Cost for the Next Generation of Physicians

Palak V. Patel, BS, BA; Alexa L. Lacy, BS; Fumiko Chino, MD
Abstract Full Text
JAMA Oncol. 2022;8(2):205-206. doi:10.1001/jamaoncol.2021.6113

This Viewpoint urges medical schools to teach cost education so that new physicians can offer patients and families the best treatment they can afford.

Invited Commentary

Insights Into Immune-Mediated Disease and Cancer Risk鈥擠elivering on the Promise of UK Biobank Big Data

Douglas R. Stewart, MD
Abstract Full Text
JAMA Oncol. 2022;8(2):219-220. doi:10.1001/jamaoncol.2021.5572

Solving the Equation of Structural Inequities in the Oncology Workforce

Frederick Lansigan, MD; Charles R. Thomas Jr, MD
Abstract Full Text
JAMA Oncol. 2022;8(2):230-231. doi:10.1001/jamaoncol.2021.6010

When Radiotherapy and Immunotherapy Dance鈥擶ho Leads So as Not to Step on Toes?

Fiyinfolu Balogun, MD, PhD; David Raben, MD
Abstract Full Text
JAMA Oncol. 2022;8(2):240-241. doi:10.1001/jamaoncol.2021.6436

Treatment for Advanced and Metastatic Thyroid Cancer Refractory to Standard Treatment鈥擶e Need to Know the When, What, and Who

Electron Kebebew, MD
Abstract Full Text
JAMA Oncol. 2022;8(2):250-251. doi:10.1001/jamaoncol.2021.6247
Cancer Care Chronicles

Pink Ribbons

Elizabeth Prsic, MD
Abstract Full Text
JAMA Oncol. 2022;8(2):207. doi:10.1001/jamaoncol.2021.6413

In this essay, a physician describes her experience learning and accepting that she is BRCA2 positive.

Poetry and Oncology

Please Say Hi to Grandpa for Us

Wendy Tong, BA
Abstract Full Text
JAMA Oncol. 2022;8(2):308. doi:10.1001/jamaoncol.2021.5978
Comment & Response

Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma鈥擜 New Standard of Care?

Matthias A. Karajannis, MD, MS; Audrey Mauguen, PhD; Kim Kramer, MD
Abstract Full Text
JAMA Oncol. 2022;8(2):301-302. doi:10.1001/jamaoncol.2021.6523

Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma鈥擜 New Standard of Care?鈥擱eply

Sarah E. S. Leary, MD; Yimei Li, PhD; James M. Olson, MD, PhD
Abstract Full Text
JAMA Oncol. 2022;8(2):302-303. doi:10.1001/jamaoncol.2021.6526

Metformin鈥擜 Thought-provoking Addition to Anticancer Therapies

Jiaqi Liang, PhD; Cheng Zhan, PhD; Qun Wang, PhD
Abstract Full Text
JAMA Oncol. 2022;8(2):303. doi:10.1001/jamaoncol.2021.6726

Metformin鈥擜 Thought-provoking Addition to Anticancer Therapies鈥擱eply

Theodoros Tsakiridis, MD, PhD; Gregory R. Pond, PhD, PStat; James Wright, MD
Abstract Full Text
JAMA Oncol. 2022;8(2):303-304. doi:10.1001/jamaoncol.2021.6729

Definitive Chemoradiotherapy for Older Patients With Esophageal Cancer

Tairo Kashihara, MD, PhD; Hiroto Ishiki, MD; Ken Kato, MD, PhD
Abstract Full Text
JAMA Oncol. 2022;8(2):304-305. doi:10.1001/jamaoncol.2021.6837

Definitive Chemoradiotherapy for Older Patients With Esophageal Cancer

Masato Hayashi, MD; Naohiro Okano, MD, PhD; Tomonori Mizutani, MD, PhD
Abstract Full Text
JAMA Oncol. 2022;8(2):305. doi:10.1001/jamaoncol.2021.6840

Definitive Chemoradiotherapy for Older Patients With Esophageal Cancer鈥擱eply

Yongling Ji, MD; Xianghui Du, MD; Ming Chen, MD
Abstract Full Text
JAMA Oncol. 2022;8(2):305-306. doi:10.1001/jamaoncol.2021.6843
Correction

Errors in Results and Discussion Sections

Abstract Full Text
free access
JAMA Oncol. 2022;8(2):306. doi:10.1001/jamaoncol.2022.0081
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2022;8(2):192. doi:10.1001/jamaoncol.2021.5481
Most Viewed(30 Days) RSS link
Most Cited(3 Years) RSS Link
View more
View more
×
Access your subscriptions
Add or change institution
Free access to newly published articles
To register for email alerts, access free PDF, and more
Purchase access
Get full journal access for 1 year
Get unlimited access and a printable PDF ($40.00)鈥�
Sign in or create a free account
Access your subscriptions
Add or change institution
Free access to newly published articles
To register for email alerts, access free PDF, and more
Purchase access
Get full journal access for 1 year
Get unlimited access and a printable PDF ($40.00)鈥�
Sign in or create a free account
Sign in to access free PDF
Add or change institution
Free access to newly published articles
To register for email alerts, access free PDF, and more
Save your search
Free access to newly published articles
To register for email alerts, access free PDF, and more
Purchase access
Make a comment
Free access to newly published articles
To register for email alerts, access free PDF, and more
Create a personal account or sign in to:
  • Register for email alerts with links to free full-text articles
  • Access PDFs of free articles
  • Manage your interests
  • Save searches and receive search alerts
Privacy Policy